Early relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitor

Gil Yosipovitch, Linda F. Stein Gold, Mark G. Lebwohl, Jonathan I. Silverberg, Anna M. Tallman, Lee T. Zane

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Pruritus occurs in all patients with atopic dermatitis and requires quick relief to reduce disease exacerbation and improve quality of life. Crisaborole ointment is a non-steroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis. This post hoc analysis explores crisaborole ointment for early relief of pruritus in patients with mild to moderate atopic dermatitis from 2 phase III studies. Patients received crisaborole or vehicle twice daily for 28 days. Pruritus was graded on a 4-point scale of none (0) to severe (3). Early improvement in pruritus required a score of none (0) or mild (1), with a ≥ 1-grade improvement from baseline on day 6. Significantly more patients experienced early improvement in pruritus with crisaborole than with vehicle (56.6% vs 39.5%; p < 0.001), including at earliest assessment (day 2, 34.3% vs 27.3%; p = 0.013). Crisaborole is a topical treatment option that can rapidly relieve atopic dermatitis-associated pruritus.

Original languageEnglish (US)
Pages (from-to)484-489
Number of pages6
JournalActa Dermato-Venereologica
Volume98
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Phosphodiesterase 4 Inhibitors
Atopic Dermatitis
Pruritus
Ointments
Disease Progression
AN2728
Quality of Life
Therapeutics

Keywords

  • Atopic dermatitis
  • Crisaborole
  • Phosphodiesterase 4 inhibitor
  • Pruritus

ASJC Scopus subject areas

  • Dermatology

Cite this

Early relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitor. / Yosipovitch, Gil; Stein Gold, Linda F.; Lebwohl, Mark G.; Silverberg, Jonathan I.; Tallman, Anna M.; Zane, Lee T.

In: Acta Dermato-Venereologica, Vol. 98, No. 5, 01.05.2018, p. 484-489.

Research output: Contribution to journalArticle

Yosipovitch, Gil ; Stein Gold, Linda F. ; Lebwohl, Mark G. ; Silverberg, Jonathan I. ; Tallman, Anna M. ; Zane, Lee T. / Early relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitor. In: Acta Dermato-Venereologica. 2018 ; Vol. 98, No. 5. pp. 484-489.
@article{8b58d7f40b4d42bbb7e5e2b308428eba,
title = "Early relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitor",
abstract = "Pruritus occurs in all patients with atopic dermatitis and requires quick relief to reduce disease exacerbation and improve quality of life. Crisaborole ointment is a non-steroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis. This post hoc analysis explores crisaborole ointment for early relief of pruritus in patients with mild to moderate atopic dermatitis from 2 phase III studies. Patients received crisaborole or vehicle twice daily for 28 days. Pruritus was graded on a 4-point scale of none (0) to severe (3). Early improvement in pruritus required a score of none (0) or mild (1), with a ≥ 1-grade improvement from baseline on day 6. Significantly more patients experienced early improvement in pruritus with crisaborole than with vehicle (56.6{\%} vs 39.5{\%}; p < 0.001), including at earliest assessment (day 2, 34.3{\%} vs 27.3{\%}; p = 0.013). Crisaborole is a topical treatment option that can rapidly relieve atopic dermatitis-associated pruritus.",
keywords = "Atopic dermatitis, Crisaborole, Phosphodiesterase 4 inhibitor, Pruritus",
author = "Gil Yosipovitch and {Stein Gold}, {Linda F.} and Lebwohl, {Mark G.} and Silverberg, {Jonathan I.} and Tallman, {Anna M.} and Zane, {Lee T.}",
year = "2018",
month = "5",
day = "1",
doi = "10.2340/00015555-2893",
language = "English (US)",
volume = "98",
pages = "484--489",
journal = "Acta Dermato-Venereologica",
issn = "0001-5555",
publisher = "Society for the Publication of Acta Dermato-Venereologica",
number = "5",

}

TY - JOUR

T1 - Early relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitor

AU - Yosipovitch, Gil

AU - Stein Gold, Linda F.

AU - Lebwohl, Mark G.

AU - Silverberg, Jonathan I.

AU - Tallman, Anna M.

AU - Zane, Lee T.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Pruritus occurs in all patients with atopic dermatitis and requires quick relief to reduce disease exacerbation and improve quality of life. Crisaborole ointment is a non-steroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis. This post hoc analysis explores crisaborole ointment for early relief of pruritus in patients with mild to moderate atopic dermatitis from 2 phase III studies. Patients received crisaborole or vehicle twice daily for 28 days. Pruritus was graded on a 4-point scale of none (0) to severe (3). Early improvement in pruritus required a score of none (0) or mild (1), with a ≥ 1-grade improvement from baseline on day 6. Significantly more patients experienced early improvement in pruritus with crisaborole than with vehicle (56.6% vs 39.5%; p < 0.001), including at earliest assessment (day 2, 34.3% vs 27.3%; p = 0.013). Crisaborole is a topical treatment option that can rapidly relieve atopic dermatitis-associated pruritus.

AB - Pruritus occurs in all patients with atopic dermatitis and requires quick relief to reduce disease exacerbation and improve quality of life. Crisaborole ointment is a non-steroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis. This post hoc analysis explores crisaborole ointment for early relief of pruritus in patients with mild to moderate atopic dermatitis from 2 phase III studies. Patients received crisaborole or vehicle twice daily for 28 days. Pruritus was graded on a 4-point scale of none (0) to severe (3). Early improvement in pruritus required a score of none (0) or mild (1), with a ≥ 1-grade improvement from baseline on day 6. Significantly more patients experienced early improvement in pruritus with crisaborole than with vehicle (56.6% vs 39.5%; p < 0.001), including at earliest assessment (day 2, 34.3% vs 27.3%; p = 0.013). Crisaborole is a topical treatment option that can rapidly relieve atopic dermatitis-associated pruritus.

KW - Atopic dermatitis

KW - Crisaborole

KW - Phosphodiesterase 4 inhibitor

KW - Pruritus

UR - http://www.scopus.com/inward/record.url?scp=85046100883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046100883&partnerID=8YFLogxK

U2 - 10.2340/00015555-2893

DO - 10.2340/00015555-2893

M3 - Article

VL - 98

SP - 484

EP - 489

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

IS - 5

ER -